Aeolus Pharmaceuticals Stock Price, News & Analysis (OTCMKTS:AOLS)

$0.08 0.00 (0.00 %)
(As of 12/13/2017 05:55 AM ET)
Previous Close$0.07
Today's Range$0.07 - $0.08
52-Week Range$0.05 - $0.25
Volume8,500 shs
Average Volume22,990 shs
Market Capitalization$12.17 million
P/E RatioN/A
Dividend YieldN/A
Beta1.49

About Aeolus Pharmaceuticals (OTCMKTS:AOLS)

Aeolus Pharmaceuticals, Inc. is a biopharmaceutical company. The Company focuses on developing a platform of compounds for use in biodefense, fibrosis, oncology, infectious disease and diseases of the central nervous system. As of September 30, 2016, the Company's platform consisted of approximately 180 compounds licensed from the University of Colorado (UC), Duke University (Duke) and National Jewish Health (NJH). The Company's lead compound is AEOL 10150, which is being developed as a medical countermeasure (MCM) against the pulmonary sub-syndrome of acute radiation syndrome (Pulmonary Acute Radiation Syndrome or Lung-ARS) and the delayed effects of acute radiation exposure (DEARE). Its other product is AEOL 11114 and AEOL 20415. AEOL 10150 is indicated for the treatment of radiation oncology and idiopathic pulmonary fibrosis. AEOL 11114 is indicated for the treatment of Parkinson's disease and epilepsy. AEOL 20415 is an orally-available, anti-infective compound.

Receive AOLS News and Ratings via Email

Sign-up to receive the latest news and ratings for AOLS and its competitors with MarketBeat's FREE daily newsletter.

Industry, Sector and Symbol

Industry Drug Manufacturers - Other
Sub-IndustryN/A
SectorMedical
SymbolOTCMKTS:AOLS
CUSIPN/A
Phone949-481-9825

Debt

Debt-to-Equity RatioN/A
Current Ratio1.31%
Quick Ratio1.31%

Price-To-Earnings

Trailing P/E RatioN/A
Forward P/E RatioN/A
P/E GrowthN/A

Sales & Book Value

Annual Sales$2.08 million
Price / Sales5.70
Cash FlowN/A
Price / CashN/A
Book Value$0.02 per share
Price / Book3.90

Profitability

Trailing EPS($0.04)
Net Income$-3,550,000.00
Net Margins-531.00%
Return on Equity-246.63%
Return on Assets-175.14%

Miscellaneous

Employees4
Outstanding Shares152,090,000

Aeolus Pharmaceuticals (OTCMKTS:AOLS) Frequently Asked Questions

What is Aeolus Pharmaceuticals' stock symbol?

Aeolus Pharmaceuticals trades on the OTCMKTS under the ticker symbol "AOLS."

How were Aeolus Pharmaceuticals' earnings last quarter?

Aeolus Pharmaceuticals Inc. (OTCMKTS:AOLS) announced its quarterly earnings results on Monday, August, 14th. The biopharmaceutical company reported ($0.01) earnings per share (EPS) for the quarter. The biopharmaceutical company earned $0.01 million during the quarter. Aeolus Pharmaceuticals had a negative return on equity of 246.63% and a negative net margin of 531.00%. View Aeolus Pharmaceuticals' Earnings History.

When will Aeolus Pharmaceuticals make its next earnings announcement?

Aeolus Pharmaceuticals is scheduled to release their next quarterly earnings announcement on Wednesday, December, 20th 2017. View Earnings Estimates for Aeolus Pharmaceuticals.

Who are some of Aeolus Pharmaceuticals' key competitors?

Who are Aeolus Pharmaceuticals' key executives?

Aeolus Pharmaceuticals' management team includes the folowing people:

  • David C. Cavalier, Chairman of the Board, Interim Chief Financial Officer (Age 45)
  • John L. McManus, President, Chief Executive Officer (Age 50)
  • John M. Clerici, Independent Director (Age 44)
  • John M. Farah Jr., Ph.D., Independent Director (Age 62)
  • Mitchell D. Kaye J.D., Independent Director (Age 46)
  • Amit Kumar Ph.D., Independent Director (Age 53)
  • Chris A. Rallis, Independent Director (Age 61)

How do I buy Aeolus Pharmaceuticals stock?

Shares of Aeolus Pharmaceuticals can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

What is Aeolus Pharmaceuticals' stock price today?

One share of Aeolus Pharmaceuticals stock can currently be purchased for approximately $0.08.

How big of a company is Aeolus Pharmaceuticals?

Aeolus Pharmaceuticals has a market capitalization of $12.17 million and generates $2.08 million in revenue each year. The biopharmaceutical company earns $-3,550,000.00 in net income (profit) each year or ($0.04) on an earnings per share basis. Aeolus Pharmaceuticals employs 4 workers across the globe.

How can I contact Aeolus Pharmaceuticals?

Aeolus Pharmaceuticals' mailing address is 26361 CROWN VALLEY PARKWAY SUITE 150, MISSION VIEJO CA, 92691. The biopharmaceutical company can be reached via phone at 949-481-9825 or via email at [email protected]


MarketBeat Community Rating for Aeolus Pharmaceuticals (AOLS)

Community Ranking:  2.0 out of 5 (star star)
Outperform Votes:  20 (Vote Outperform)
Underperform Votes:  31 (Vote Underperform)
Total Votes:  51
MarketBeat's community ratings are surveys of what our community members think about Aeolus Pharmaceuticals and other stocks. Vote "Outperform" if you believe the stock will outperform the S&P 500 over the long term. Vote "Underperform" if you believe the stock will underperform the S&P 500 over the long term. You may vote once every thirty days.

Analyst Ratings

Aeolus Pharmaceuticals (OTCMKTS:AOLS) Analyst Ratings History


No equities research coverage for this company has been tracked by MarketBeat

Earnings

Aeolus Pharmaceuticals (OTCMKTS:AOLS) Earnings History and Estimates Chart

Earnings by Quarter for Aeolus Pharmaceuticals (OTCMKTS:AOLS)

Aeolus Pharmaceuticals (OTCMKTS AOLS) Earnings History by Quarter

DateQuarterConsensus EstimateActual EPSRevenue EstimateActual RevenueRelease LinkConference CallDetails
12/20/2017        
8/14/2017Q3 2017($0.01)$0.01 millionViewN/AView Earnings Details
5/15/2017Q2 2017($0.01)$0.13 millionViewN/AView Earnings Details
2/17/2017Q1 2017($0.01)$0.08 millionViewN/AView Earnings Details
8/17/2015Q3 2015($0.01)$0.06 millionViewN/AView Earnings Details
2/13/2015Q1 2015($0.01)$0.93 millionViewN/AView Earnings Details
(Data available from 1/1/2011 forward)

Estimates

Aeolus Pharmaceuticals (OTCMKTS:AOLS) Earnings Estimates

No earnings estimates for this company have been tracked by MarketBeat.com

Dividends

Dividend History for Aeolus Pharmaceuticals (OTCMKTS:AOLS)


No dividend announcements for this company have been tracked by MarketBeat.com

Insider Trades

Aeolus Pharmaceuticals (OTCMKTS AOLS) Insider Trading and Institutional Ownership History

Insider Ownership Percentage: 66.60%
Insider Trades by Quarter for Aeolus Pharmaceuticals (OTCMKTS:AOLS)

Aeolus Pharmaceuticals (OTCMKTS AOLS) Insider Trades by Quarter

Transaction DateInsider NameTitleBuy/SellNumber of SharesAverage Share PriceTotal TransactionDetails
3/6/2013John L McmanusCEOBuy10,000$0.35$3,500.00View SEC Filing  
(Data available from 1/1/2013 forward)

Headlines

Aeolus Pharmaceuticals (OTCMKTS AOLS) News Headlines

Source:

SEC Filings

Aeolus Pharmaceuticals (OTCMKTS:AOLS) SEC Filings

This page is loading this company's SEC Filings. Please wait...

Social Media

Financials

Aeolus Pharmaceuticals (OTCMKTS:AOLS) Income Statement, Balance Sheet and Cash Flow Statement

Chart

Aeolus Pharmaceuticals (OTCMKTS AOLS) Stock Chart for Wednesday, December, 13, 2017

Loading chart…

This page was last updated on 12/13/2017 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.